Document is current
Any future updates will be listed below
-
Authors
Faria, Giselle M. http://orcid.org/0000-0002-4287-1651
Soares, Igor D. P.
D’Alincourt Salazar, Marcela
Amorim, Marcia R.
Pessoa, Bruno L.
da Fonseca, Clovis O.
Quirico-Santos, Thereza http://orcid.org/0000-0003-0501-8720
-
Funding
Funding for this research was provided by:
Euclides da Cunha Foundation - UFF (3662)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Fellowship)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (MCT/CNPq/CT-Saude 401943/2010-0; CNPq/Universal 481059/2011-3)
- License Information
-
More Information
Article History
Received: 29 January 2020
Accepted: 29 March 2020
First Online: 7 April 2020
Ethics approval and consent to participate
: All procedures were carried out with patients with recurrent GBM attending the out-patient Neurosurgical Unit in the Antonio Pedro University Hospital and enrolled on Phase I/II clinical trial to assess the efficacy of intranasal administration of the monoterpene POH. This project was approved by Institutional and National Ethics Committees (HUAP/UFF: CAAE 0085.0.258.000–08; CONEP registration 9681 n<sup>o</sup>. 25000.009267 / 2004) being also in compliance with the 1964 Helsinki Convention for clinical study and its latter amendments or comparable ethical standards. Written informed consent prior to enrollment in the clinical trial of intranasal POH was obtained from all individual participants included in the study.Perillyl alcohol was formulated to be used by inhalation by the University Pharmacy in accordance with international patent application US Patent Application 20040087651 May 6, 2004 and Brazilian PI0107262–5 with approval by local Board of Health.
: Not applicable, since no personal information is provided in this manuscript.
: The authors declare no conflict of interest concerning this manuscript. All authors read and approved the final version of the present manuscript
